Semaglutide Sequence
Understanding the exact amino acid sequence and chemical modifications of semaglutide is essential for investigators studying glucagon-like peptide-1 (GLP-1) receptor agonists. This reference guide details the primary sequence, structural alterations designed to resist enzymatic degradation, and analytical verification methods required for rigorous laboratory research.
Quick answer
Understanding the exact amino acid sequence and chemical modifications of semaglutide is essential for investigators studying glucagon-like peptide-1 (GLP-1) receptor agonists. This reference guide details the primary sequence, structural alterations designed to resist enzymatic degradation, and analytical verification methods required for rigorous laboratory research.
Key takeaways
- The [semaglutide](/research-peptides/semaglutide) sequence is a 31-amino acid synthetic peptide analog derived from human glucagon-like peptide-1 (GLP-1(7-37)).
- Native human GLP-1(7-37) exhibits a brief biological half-life in physiological media due to rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) between the second and third N-terminal residues (Ala8-Glu9).
- The gross empirical formula for [semaglutide](/research-peptides/semaglutide) is C187H291N45O59, with a calculated monoisotopic mass of approximately 4111.15 Da and a chemical molecular weight of 4113.58 g/mol.
- Preclinical studies indicate that the [semaglutide](/research-peptides/semaglutide) sequence functions as a potent agonist at the human GLP-1 receptor (GLP-1R), a G-protein-coupled receptor primarily expressed on pancreatic beta cells and specific central nervous system pathways.
Exact Semaglutide Amino Acid Sequence
The semaglutide sequence is a 31-amino acid synthetic peptide analog derived from human glucagon-like peptide-1 (GLP-1(7-37)). Its full primary sequence is His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.
In this sequence, alpha-aminobutyric acid (Aib) replaces alanine at position 8 (corresponding to position 2 of native GLP-1), while the lysine residue at position 26 is covalently conjugated to a hydrophobic C18 fatty diacid side chain via a glutamate-containing hydrophilic linker. These targeted modifications preserve affinity for the target receptor while significantly extending metabolic half-life during in vitro and in vivo laboratory investigations.
Structural Modifications and Enzymatic Resistance
Native human GLP-1(7-37) exhibits a brief biological half-life in physiological media due to rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) between the second and third N-terminal residues (Ala8-Glu9). In the synthesized semaglutide sequence, replacing alanine with the unnatural amino acid alpha-aminoisobutyric acid (Aib) creates steric hindrance that blocks DPP-4 recognition without disrupting N-terminal binding to the extracellular domain of the GLP-1 receptor.
Furthermore, the site-specific conjugation at Lys26 utilizes a specialized linker comprising two 8-amino-3,6-dioxaoctanoic acid (AEEAc) units and a gamma-glutamic acid residue attached to a terminal C18 fatty diacid. This non-covalent albumin-binding moiety promotes reversible association with serum proteins in culture assays and rodent models, reducing renal clearance rates and altering overall peptide disposition.
Physicochemical Properties and Molecular Mass
The gross empirical formula for semaglutide is C187H291N45O59, with a calculated monoisotopic mass of approximately 4111.15 Da and a chemical molecular weight of 4113.58 g/mol. Precision molecular mass verification forms the primary baseline for confirming sequence identity in modern analytical workflows.
When analyzing high-purity research peptides, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or electrospray ionization liquid chromatography-mass spectrometry (ESI-LC/MS) is utilized to verify the exact charge-to-mass ratio (m/z). Observed spectra must match theoretical mass values to confirm that the C18 fatty diacid acyl chain and hydrophilic linker are fully intact without truncation products or unreacted intermediates.
GLP-1 Receptor Affinity and Signaling Pathways
Preclinical studies indicate that the semaglutide sequence functions as a potent agonist at the human GLP-1 receptor (GLP-1R), a G-protein-coupled receptor primarily expressed on pancreatic beta cells and specific central nervous system pathways. Binding of the peptide's N-terminal sequence triggers activation of adenylate cyclase, resulting in intracellular cyclic adenosine monophosphate (cAMP) accumulation.
In vitro functional assays measuring intracellular cAMP levels demonstrate that semaglutide maintains high potency, exhibiting sub-nanomolar EC50 values in recombinant cell lines expressing GLP-1R. Additional downstream signaling cascades characterized in laboratory models include protein kinase A (PKA) activation and extracellular signal-regulated kinase (ERK1/2) phosphorylation, establishing a standardized molecular readout for receptor engagement.
Comparative Analysis Within the Incretin Metic Class
Researchers evaluating incretin mimetic pathways frequently compare the semaglutide sequence against other multi-receptor or single-receptor agonists to analyze binding kinetics and structural divergence. While semaglutide specifically targets GLP-1R with high selectivity, liraglutide structure features a shorter C16 palmitoyl chain at Lys26 and retains native Ala8, making it more susceptible to DPP-4 cleavage.
In contrast, dual-agonists such as tirzepatide incorporate a 39-amino acid sequence derived from gastric inhibitory polypeptide (GIP) with a C20 fatty diacid moiety, enabling balanced activation across both GLP-1 and GIP receptors. Newer experimental triple-agonists like retatrutide integrate glucagon receptor activity into a single modified backbone. Comparing these distinct primary sequences helps researchers clarify how subtle molecular variations alter signaling bias and receptor internalisation.
Laboratory Reconstitution and Solubilization Protocol
Lyophilized semaglutide trifluoroacetate or acetate salt presents as a white to off-white dense cake or powder. Due to the presence of the hydrophobic lipid side chain, reconstitution protocols require specific buffer systems to avoid aggregation or incomplete dissolution.
For standardized in vitro assays, reconstitution in sterile phosphate-buffered saline (PBS, pH 7.4) or dilute aqueous buffers is recommended. Initial wetting with a minimal volume of 10–20 mM sodium phosphate buffer or sterile water before diluting into working media prevents precipitation. Avoid vigorous vortexing; gentle inversion or room-temperature equilibration for 10–15 minutes ensures uniform dissolution without creating shear stress that could denature the tertiary structure of sensitive analogs.
Storage Conditions and Peptide Stability
Lyophilized research compounds should be stored desiccated at -20°C or -80°C for long-term preservation, protected from direct light exposure. Under sub-zero desiccated conditions, high-purity semaglutide remains stable for extended periods without significant degradation or oxidation of sensitive residues like tryptophan or tyrosine.
Once reconstituted into aqueous solutions, working aliquots should be prepared immediately to eliminate repeated freeze-thaw cycles. Reconstituted solutions are typically stable at 2°C to 8°C for short duration analytical testing (1–2 weeks), whereas long-term solution storage requires freezing at -80°C in polypropylene tubes to minimize surface adsorption.
Quality Verification: HPLC, MS, and Endotoxin Standards
Assessing compound integrity requires rigorous quality control procedures. Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) using C4 or C18 stationary phases provides clear separation of the main semaglutide sequence from related synthesis impurities, such as des-Aib sequences, truncated fragments, or oxidized species. A purity threshold of ≥99% by HPLC area is standard for high-tier analytical work.
To ensure compliance with strict experimental criteria, every lot supplied by PX1 Research undergoes rigorous testing in ISO 17025 accredited facilities. Characterization includes ESI-MS for exact molecular weight verification, high-resolution RP-HPLC chromatograms, and Chromogenic Reagent LAL endotoxin testing ensuring levels below 0.1 EU/mg. Investigators can access detailed, lot-specific certificates of analysis (COA) directly through our research library or product documentation portal.
PX1 Research Manufacturing and Supplier Assurance
Precision in peptide synthesis depends on modern solid-phase peptide synthesis (SPPS) techniques utilizing orthogonally protected amino acid derivatives. PX1 Research synthesizes all compounds under stringent, GMP-compliant laboratory protocols within USA-based manufacturing facilities located in California and Arizona.
Whether sourcing standard analytical quantities or arranging volume supply through a wholesale lab account, researchers receive fully traceable compounds supported by comprehensive analytical data packages. Every shipment ships directly from our domestic facilities, providing reliable lot-to-lot consistency for preclinical and in vitro research protocols.
Frequently Asked Questions
What is the exact primary sequence of semaglutide?
The semaglutide sequence is His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.
How does Aib substitution at position 8 protect against DPP-4 degradation?
Replacing native alanine with alpha-aminoisobutyric acid (Aib) introduces steric hinderance near the N-terminus. This structural change prevents dipeptidyl peptidase-4 (DPP-4) from cleaving the N-terminal His7-Aib8 bond, significantly extending peptide stability in biological assays.
What is the role of the C18 fatty diacid side chain at Lysine-26?
The C18 fatty diacid acyl chain attached to Lys26 via a hydrophilic linker promotes reversible, non-covalent binding to albumin. This interaction reduces renal filtration and prolongs circulating availability during preclinical in vivo protocols.
How is the purity of the semaglutide sequence verified?
Purity is measured using reversed-phase high-performance liquid chromatography (RP-HPLC) coupled with mass spectrometry (ESI-MS or MALDI-TOF). PX1 Research guarantees ≥99% purity verified by lot-specific COAs.
What buffer is recommended for solubilizing lyophilized semaglutide?
Standard phosphate-buffered saline (PBS, pH 7.4) or 10–20 mM sodium phosphate aqueous solutions are ideal. Reconstitution should involve gentle swirling without harsh vortexing to preserve peptide structural integrity.
What is the acceptable endotoxin threshold for research-grade semaglutide?
For reliable cell culture and preclinical assays, endotoxin levels should remain below 0.1 EU/mg, as quantified by Limulus Amebocyte Lysate (LAL) testing.
How does semaglutide sequence differ from native GLP-1(7-37)?
Semaglutide exhibits two primary structural differences from native GLP-1(7-37): an Aib substitution at position 8 (resisting DPP-4) and a Lys26 substitution linked to a hydrophilic spacer and C18 fatty diacid.
Where are PX1 Research peptides manufactured and tested?
All PX1 Research compounds are USA-manufactured in GMP-compliant facilities and tested by independent ISO 17025 accredited laboratories.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.